No Cover Image

Journal article 210 views

Repurposing metabolic drugs as anti-inflammatory agents

Andrew E. Hogan Orcid Logo, Cian Davis, Benjamin Jenkins, Nick Jones Orcid Logo, Donal O’Shea Orcid Logo

Trends in Endocrinology & Metabolism

Swansea University Authors: Benjamin Jenkins, Nick Jones Orcid Logo

Full text not available from this repository: check for access using links below.

Check full text

DOI (Published version): 10.1016/j.tem.2025.07.003

Abstract

Dysregulation of bodyweight systemic metabolism is intrinsically linked to an inflammatory phenotype, with each underpinning the other. Over the past decade, new classes of drug, such as glucagon-like peptide-1 (GLP-1)-based therapies and sodium glucose co-transporter 2 (SGLT2) inhibitors, have ente...

Full description

Published in: Trends in Endocrinology & Metabolism
ISSN: 1043-2760 1879-3061
Published: Elsevier BV 2025
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa70229
first_indexed 2025-08-26T12:01:01Z
last_indexed 2025-11-07T07:34:01Z
id cronfa70229
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2025-11-06T11:13:02.9312182</datestamp><bib-version>v2</bib-version><id>70229</id><entry>2025-08-26</entry><title>Repurposing metabolic drugs as anti-inflammatory agents</title><swanseaauthors><author><sid>90f7cfd66781feba615436189178a528</sid><firstname>Benjamin</firstname><surname>Jenkins</surname><name>Benjamin Jenkins</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>0fce0f7ddbdbfeb968f4e2f1e3f86744</sid><ORCID>0000-0003-4846-5117</ORCID><firstname>Nick</firstname><surname>Jones</surname><name>Nick Jones</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2025-08-26</date><deptcode>MEDS</deptcode><abstract>Dysregulation of bodyweight systemic metabolism is intrinsically linked to an inflammatory phenotype, with each underpinning the other. Over the past decade, new classes of drug, such as glucagon-like peptide-1 (GLP-1)-based therapies and sodium glucose co-transporter 2 (SGLT2) inhibitors, have entered the clinical management of bodyweight and metabolic disease with great success. With their expanded use, it is emerging that the benefits of these drugs extend beyond metabolic improvements into changes in chronic inflammation, potentially independent of those in metabolism. In this review, we discuss the impact of metabolic drugs on inflammatory comorbidities of metabolic disorders and beyond. We highlight the molecular mechanisms via which these drugs exert their anti-inflammatory actions and discuss their potential repurposing as direct anti-inflammatory agents.</abstract><type>Journal Article</type><journal>Trends in Endocrinology &amp; Metabolism</journal><volume>0</volume><journalNumber/><paginationStart/><paginationEnd/><publisher>Elsevier BV</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>1043-2760</issnPrint><issnElectronic>1879-3061</issnElectronic><keywords>obesity; glucagon-like peptide-1; SLGT2i; inflammation</keywords><publishedDay>13</publishedDay><publishedMonth>8</publishedMonth><publishedYear>2025</publishedYear><publishedDate>2025-08-13</publishedDate><doi>10.1016/j.tem.2025.07.003</doi><url/><notes>Review</notes><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm>Another institution paid the OA fee</apcterm><funders>A.E.H. and D.O.S. are supported by a Health Research Board Grant (ILP-POR-2024-019). N.J. is supported by an MRC New Investigator Research Grant (MR/X000095/1).</funders><projectreference/><lastEdited>2025-11-06T11:13:02.9312182</lastEdited><Created>2025-08-26T12:59:54.0621543</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Biomedical Science</level></path><authors><author><firstname>Andrew E.</firstname><surname>Hogan</surname><orcid>0000-0001-5875-230x</orcid><order>1</order></author><author><firstname>Cian</firstname><surname>Davis</surname><order>2</order></author><author><firstname>Benjamin</firstname><surname>Jenkins</surname><order>3</order></author><author><firstname>Nick</firstname><surname>Jones</surname><orcid>0000-0003-4846-5117</orcid><order>4</order></author><author><firstname>Donal</firstname><surname>O&#x2019;Shea</surname><orcid>0000-0002-1408-5274</orcid><order>5</order></author></authors><documents/><OutputDurs/></rfc1807>
spelling 2025-11-06T11:13:02.9312182 v2 70229 2025-08-26 Repurposing metabolic drugs as anti-inflammatory agents 90f7cfd66781feba615436189178a528 Benjamin Jenkins Benjamin Jenkins true false 0fce0f7ddbdbfeb968f4e2f1e3f86744 0000-0003-4846-5117 Nick Jones Nick Jones true false 2025-08-26 MEDS Dysregulation of bodyweight systemic metabolism is intrinsically linked to an inflammatory phenotype, with each underpinning the other. Over the past decade, new classes of drug, such as glucagon-like peptide-1 (GLP-1)-based therapies and sodium glucose co-transporter 2 (SGLT2) inhibitors, have entered the clinical management of bodyweight and metabolic disease with great success. With their expanded use, it is emerging that the benefits of these drugs extend beyond metabolic improvements into changes in chronic inflammation, potentially independent of those in metabolism. In this review, we discuss the impact of metabolic drugs on inflammatory comorbidities of metabolic disorders and beyond. We highlight the molecular mechanisms via which these drugs exert their anti-inflammatory actions and discuss their potential repurposing as direct anti-inflammatory agents. Journal Article Trends in Endocrinology & Metabolism 0 Elsevier BV 1043-2760 1879-3061 obesity; glucagon-like peptide-1; SLGT2i; inflammation 13 8 2025 2025-08-13 10.1016/j.tem.2025.07.003 Review COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University Another institution paid the OA fee A.E.H. and D.O.S. are supported by a Health Research Board Grant (ILP-POR-2024-019). N.J. is supported by an MRC New Investigator Research Grant (MR/X000095/1). 2025-11-06T11:13:02.9312182 2025-08-26T12:59:54.0621543 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Biomedical Science Andrew E. Hogan 0000-0001-5875-230x 1 Cian Davis 2 Benjamin Jenkins 3 Nick Jones 0000-0003-4846-5117 4 Donal O’Shea 0000-0002-1408-5274 5
title Repurposing metabolic drugs as anti-inflammatory agents
spellingShingle Repurposing metabolic drugs as anti-inflammatory agents
Benjamin Jenkins
Nick Jones
title_short Repurposing metabolic drugs as anti-inflammatory agents
title_full Repurposing metabolic drugs as anti-inflammatory agents
title_fullStr Repurposing metabolic drugs as anti-inflammatory agents
title_full_unstemmed Repurposing metabolic drugs as anti-inflammatory agents
title_sort Repurposing metabolic drugs as anti-inflammatory agents
author_id_str_mv 90f7cfd66781feba615436189178a528
0fce0f7ddbdbfeb968f4e2f1e3f86744
author_id_fullname_str_mv 90f7cfd66781feba615436189178a528_***_Benjamin Jenkins
0fce0f7ddbdbfeb968f4e2f1e3f86744_***_Nick Jones
author Benjamin Jenkins
Nick Jones
author2 Andrew E. Hogan
Cian Davis
Benjamin Jenkins
Nick Jones
Donal O’Shea
format Journal article
container_title Trends in Endocrinology & Metabolism
container_volume 0
publishDate 2025
institution Swansea University
issn 1043-2760
1879-3061
doi_str_mv 10.1016/j.tem.2025.07.003
publisher Elsevier BV
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Biomedical Science{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Biomedical Science
document_store_str 0
active_str 0
description Dysregulation of bodyweight systemic metabolism is intrinsically linked to an inflammatory phenotype, with each underpinning the other. Over the past decade, new classes of drug, such as glucagon-like peptide-1 (GLP-1)-based therapies and sodium glucose co-transporter 2 (SGLT2) inhibitors, have entered the clinical management of bodyweight and metabolic disease with great success. With their expanded use, it is emerging that the benefits of these drugs extend beyond metabolic improvements into changes in chronic inflammation, potentially independent of those in metabolism. In this review, we discuss the impact of metabolic drugs on inflammatory comorbidities of metabolic disorders and beyond. We highlight the molecular mechanisms via which these drugs exert their anti-inflammatory actions and discuss their potential repurposing as direct anti-inflammatory agents.
published_date 2025-08-13T14:18:07Z
_version_ 1851040608662061056
score 11.089677

Similar Items